Provectus Biopharmaceuticals, founded in Knoxville, Tennessee, is a clinical-stage biotechnology company dedicated to developing innovative immunotherapy medicines. Their core mission is to create safe, affordable, and accessible treatments that maximize curative impact for patients worldwide. The company focuses on pioneering therapies for various cancers, including skin, liver, and breast cancer. Their leading investigational drug, PV-10, is an ablative immunotherapy currently under investigation for its efficacy in treating solid tumor cancers.

Notable figures associated with Provectus Biopharmaceuticals include key researchers and industry experts who drive their innovative research and development efforts. The company has garnered attention and investment from various stakeholders in the medical and biotech communities. Among its key achievements is the advancement of PV-10 through clinical trials, showcasing promising results in cancer treatment. Provectus Biopharmaceuticals continues to make a significant impact by striving to bring groundbreaking, cost-effective cancer therapies to patients globally.